Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Gains from Sales and Divestitures (2024 - 2025)

Historic Gains from Sales and Divestitures for 4D Molecular Therapeutics (FDMT) over the last 2 years, with Q3 2025 value amounting to $113785.0.

  • 4D Molecular Therapeutics' Gains from Sales and Divestitures rose 24959.14% to $113785.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $113785.0, marking a year-over-year increase of 24959.14%. This contributed to the annual value of $52884.0 for FY2024, which is N/A changed from last year.
  • As of Q3 2025, 4D Molecular Therapeutics' Gains from Sales and Divestitures stood at $113785.0, which was up 24959.14% from $70278.0 recorded in Q2 2025.
  • In the past 5 years, 4D Molecular Therapeutics' Gains from Sales and Divestitures ranged from a high of $113785.0 in Q3 2025 and a low of $10996.0 during Q1 2024